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Abstract
Chronic Liver Disease (CLD) is one of the top causes of morbidity and mortality globally.
Among the spectrum of liver diseases, non-alcoholic steatohepatitis (NASH) is the most
common cause of cirrhosis and one of the top reasons for a liver transplant. Patients with NASH
end up with hepatic decompensation and liver-related complications such as malnutrition,
sarcopenia, frailty, and death. Telemedicine has transformed health care by improving access,
reducing cost, and increasing the quality of care. However, telemedicine has not been widely
used to manage patients with CLD. This DNP project created a telemedicine protocol to manage
patients with NASH, implemented the project at a transplant facility, and evaluated the
effectiveness of the intervention using preliminary data from visits one and two. Although a
larger sample size and longer study duration are needed, the telemedicine protocol appears to
improve patient clinical outcomes as evidenced by a significant decrease in weight and BMI,
fewer liver-related hospitalizations, no ED or urgent care visits, and improvement on patients’
perception of activity level and worry score. No significant changes noted in the patients’
MELD-Na score, overall health-related quality of life, frailty, and malnutrition status.

x

Chapter 1
Introduction
Telemedicine, derived from the Latin word “medicus” and the Greek word “tele,” was
first defined in the 1970s by Thomas Bird, which means healing at a distance (Dinevski et al.,
2011). The World Health Organization (2010) defined telemedicine and telehealth as the delivery
of health care services by using advances in technology to promote the health of individuals and
communities. Telemedicine refers explicitly to the use of electronic information and
telecommunications technologies to render clinical services (Health Resources Services
Administration, 2019). Due to recent advancements in technology and increasing availability,
telemedicine is now widely used in different health care fields with great success in improving
patient outcomes (Du Toit et al., 2019; Marcolino et al., 2019; Michaud et al., 2020).
Furthermore, the COVID-19 pandemic has dramatically transformed health care and
telemedicine services. Innovations in telemedicine can enhance the delivery of care in patients
with chronic liver disease.
Chronic liver disease (CLD) is a public health threat and a burden to society. It is one of
the top causes of morbidity and mortality in the world. The Centers for Disease Control and
Prevention (2019) estimated that 1.8% or 4.5 million adults have liver disease in the United
States. In 2017, 41,743 died from liver disease in the United States, and more than 1.32 million
died from cirrhosis globally (GBD 2017 Cirrhosis Collaborators, 2020). Having a liver disease is
also associated with higher health care expenditure, approximately $19,390 per year. Without
considering hepatitis C costs, the direct cost of chronic liver disease was $2.5 billion, and the
indirect cost was $10.6 billion in 2004. Health care utilization and costs were nearly $14,000 per
patient per year in 2015. Chronic liver disease-related inpatient hospitalization cost was
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approximately $18.8 billion in 2016 (Hirodge et al., 2020). Furthermore, patients with chronic
liver disease are more likely to have depressive symptoms, poor health-related quality of life
(HRQoL), and lower health utility scores (Stepanova et al., 2017).
Non-alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease, or NAFLD, is an emerging liver disease associated with
metabolic syndrome (Chalasani et al., 2018). It is defined as the presence of fat in the liver in the
absence of secondary causes of hepatic steatosis. It is commonly associated with risk factors for
metabolic syndrome, such as obesity, insulin resistance, diabetes, hypertension, and dyslipidemia
(Younossi, 2019). NAFLD has two components: non-alcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH).
The global prevalence of non-alcoholic fatty liver disease is 24.24% (Younossi, Koenig,
et al., 2016). The worldwide incidence rate ranges from 28.01 to 52.34 per 1,000 person-years.
Approximately 76% of people with diabetes and 90% of people with obesity have NAFLD. The
prevalence of NAFLD has increased in parallel with rising obesity and diabetes rates (Sundaram
et al., 2009; Younossi, 2019). In the United States, mortality from non-alcoholic fatty liver
disease increased between 2007 to 2016 (Kim et al., 2018).
Non-alcoholic fatty liver disease is a burden to the economy. NAFLD’s annual medical
and societal costs are estimated $292 billion annually (Perumpail et al., 2017). Approximately
$87 billion accounted for NAFLD alone in all age groups. In 2010, the Medicare median annual
hospitalization cost was $11,000 per patient, and the median yearly outpatient cost was between
$3,308 ± 5,132 (Shetty & Syn, 2019). Due to the rising healthcare utilization, the expected 10year economic burden of the disease is estimated to be over a trillion dollars in the United States
(Younossi, Blisset, et al., 2016).
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Problem Statement
The American Association for the Study of Liver Diseases (2020) has defined evidencebased guidelines standardizing the management and care for patients with chronic liver disease.
However, despite clear guidelines, patients with CLD often receive suboptimal care and fail to
receive treatments as recommended (Buchanan et al., 2014; Kanwal et al., 2012; Wong et al.,
2009). Furthermore, the National Health Interview Survey (NHIS) 2013-2017 revealed that
patients with CLD have higher rates of poor health and barriers than other diseases (Wong et al.,
2019). Identified barriers to care include appointments, access, and finances. Telemedicine can
reduce the quality gaps and overcome barriers to care among patients with liver disease. Besides,
telemedicine offers various advantages, including enhancing access to care, improving clinical
management, enhancing communication between patients and providers, increasing patient
satisfaction, improving patient outcomes, and reducing health care costs.
Among the spectrum of liver diseases, non-alcoholic steatohepatitis is the most common
cause of cirrhosis and one of the top reasons for a liver transplant (Byrne & Targher, 2015; Pais
et al., 2016; Sheka et al., 2020; Tesfay et al., 2018; Younossi et al., 2018). It is associated with
increased rates of liver-specific morbidity and mortality (Mantovani et al., 2020; Oaik et al.,
2019; Sarwar et al., 2018). A liver transplant is a treatment option. However, organ shortage has
made it difficult for liver transplant candidates to get transplanted. Therefore, patients with
NASH end up with hepatic decompensation and liver-related complications such as malnutrition,
sarcopenia, frailty, and death (Bhanji et al., 2019; Li et al., 2020; Palmer et al., 2019).
To address this problem of suboptimal care, this DNP project developed a telemedicine
protocol to optimize the delivery of care among patients with NASH. The protocol includes a
monthly telemedicine appointment with the liver transplant multi-disciplinary team. The team
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consists of a transplant hepatologist, a transplant surgeon, a nurse practitioner, and a registered
dietitian. This project aimed to address patients' needs, reduce readmissions, improve patient
outcomes, and increase patient satisfaction.
Significance
Non-alcoholic steatohepatitis is associated with severe liver-related complications and a
high death rate. The overall mortality rate for NASH is 25.56 per 1,000 person-years (Paik et al.,
2019; Younossi et al., 2019). The common complications of CLD include hepatic
encephalopathy, upper gastrointestinal bleeding, ascites requiring paracentesis, and spontaneous
bacterial peritonitis. Such decompensating events often lead to frequent emergency department
visits and hospitalizations. To overcome these challenges, telemedicine should be utilized to
prevent, monitor, and control complications from NASH.
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Chapter 2
Review of Literature
Telemedicine has transformed health care by improving access to care, reducing cost, and
increasing care quality. However, despite evidence showing its benefits, telemedicine has not
been widely used to manage patients with chronic liver disease clinically. This literature review
examined the evidence available on telemedicine in patients with liver problems, focusing on the
clinical outcomes and methodologies for evaluation.
Search Strategy
A literature review of telemedicine use on CLD was conducted using the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses or PRISMA guidelines (Moher et
al., 2009; Oermann & Hays, 2019). The key questions identified for this literature review were:
(1) Is telemedicine feasible in managing patients with CLD? (2) How does telemedicine impact
the clinical outcomes of patients with CLD? (3) What tools are used to evaluate the effects of
telemedicine and the severity of CLD? And (4) does the use of telemedicine improve patient
satisfaction?
PubMed and Embase electronic databases were used to find the best literature that
addresses the phenomenon. Boolean operators and MeSH terms used were “chronic liver
disease” or “CLD” or “liver disease,” and “telemedicine” or “telehealth” or “telenursing.” The
inclusion criteria included patients with liver disease, any electronic health interventions, and
health-related outcomes.
The initial searches identified 406 articles through PubMed and Embase databases.
Results were filtered to show only articles with full-text availability, which resulted in 325
publications. Further modifications were made for the following exclusionary criteria: abstracts,
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articles in the press, short surveys, and youths or adolescents. Twenty-seven duplicates were
removed from the list, which yielded 222 articles. The abstracts were screened afterward. One
hundred thirteen publications had participants with a diagnosis other than chronic liver disease,
and those studies were excluded. Seventy-nine articles were studies on interventions not
considered electronic health interventions (telemedicine, telehealth, or telenursing). These
articles were then removed from the list.
The thirty articles were screened in full text for relevance. Nineteen articles that provided
expert opinions and recommendations on telemedicine were excluded. The last eleven
publications were further analyzed. Two studies focused on patients with comorbidities and were
considered irrelevant for the review. Two other articles were excluded due to the limited
outcomes presented. The seven most relevant articles were selected for the literature review. An
adapted PRISMA flow diagram was created to show the details of the article selection process
(see Appendix A for the Adapted PRISMA Flow Diagram).
Data Extraction
Pertinent data were extracted from the final seven literature that met the review inclusion
and exclusion criteria. The article title, authors, year of publication, academic journal, purpose,
objective, level of evidence, sample, methods, design, results, strengths, weaknesses and
limitations, and contribution to science and/or practice were organized into an evidence table.
See Appendix B for the Evidence Table.
For ease of analysis and comparison, specific data for each study were synthesized in the
evidence table, such as participant information, diagnosis, studies’ characteristics and findings,
study time frames, data collection methods, and validated tools used to evaluate outcomes. In
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addition, the quality of each study, including strengths, limitations, risk of bias, and summary,
were included in the evidence table.
Synthesis of the Literature
The studies included in the literature review focused on interventions delivered through
telemedicine. One study was a randomized control trial. Three literatures were systematic
reviews of cohort studies, and the remaining three were cohort studies. Barnett et al. (2020),
Javanmardifard et al. (2017), and Mazzotti et al. (2018) explored the efficacy of telemedicine
programs in modifying lifestyle behaviors. The studies by Konjeti et al. (2019), Le et al. (2019),
Mauro et al. (2020), and Su et al. (2018) looked at how telemedicine streamlines patient care and
improves liver-disease. In addition, the studies by Barnett et al., Le et al., and Mauro et al.
investigated its effect on patient satisfaction. While the interventions and methods in the
literature varied, the evidence in this review concluded that telemedicine was an effective tool for
improving clinical outcomes and patient satisfaction.
Literature Findings
All seven studies concluded that the use of telemedicine in managing patients with
chronic liver disease was feasible. The studies also found a strong association between
telemedicine use, improved quality of care, and improved patient outcomes. In addition,
telemedicine improved patient satisfaction.
The interventions delivered through telemedicine included provider consultations and
follow-ups, lifestyle modification programs, and nutritional counseling. The studies by Barnett et
al. (2020), Javanmardifard et al. (2017), and Mazzoti et al. (2018) aimed at interventions to
promote healthy behaviors via telemedicine. Study results showed improved patients’ self-care
habits, including physical and nutritional habits. In addition, the patients reported positive
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experiences with telemedicine and an increased desire to engage in healthier behaviors.
Furthermore, two studies compared interventions delivered through telemedicine versus inperson interventions (Javanmardifard et al., 2017; Mazzotti et al., 2018). The studies found that
the participants’ nutritional behavior and physical activity levels significantly increased with
telemedicine. In addition, the attrition rate was noted to be considerably lower among the
telemedicine group.
The literature review also strongly suggested that telemedicine use in patients with liver
disease improved their overall health. Su et al. (2018) found that telemedicine helped address
liver-related issues such as variceal screening and hepatocellular carcinoma screening. However,
in comparing telemedicine with regular in-person appointments with a hepatologist, no
significant difference was found in the patient survival rate. A higher survival rate was seen in
the telemedicine group compared to the no-visit group. Telemedicine did not affect the
participants’ alcohol use. Additionally, significant weight loss and a decrease in liver enzymes
were noted by Mazotti et al. (2018).
The studies also found that telemedicine improved the quality of care. The studies by
Konjeti et al. (2019), Mauro et al. (2020), Le et al. (2019), and Su et al. (2018) streamlined care,
minimized unnecessary testing, and reduced health care costs. For example, Konjeti et al. found
that telemedicine reduced transplant evaluations by 60% and decreased costs by preventing
unnecessary consultations and testing (Konjeti et al., 2019).
The use of telemedicine led to shorter waiting times, decreased patient barriers to care,
and improved patient satisfaction (Barnett et al., 2020; Le et al., 2019; Mauro et al., 2020).
Telemedicine was well-accepted by the patients. The participants reported having positive
experiences with telemedicine – better than traditional visits and less burden on travel. In the
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study by Le et al., patients reported a moderate to a high level of satisfaction with telemedicine.
On the contrary, the study found no significant difference in patient satisfaction compared to the
control group.
Limitations
There were multiple limitations identified in this literature review. First, all the studies
varied the study designs, objectives, interventions, inclusion and exclusion criteria, methods, and
results. Barnett et al. (2020) did qualitative research focusing on lifestyle interventions delivered
via telehealth. Javanmardifard et al. (2017) performed a randomized control trial to determine the
efficacy of telenursing on lifestyle changes. Konjeti et al. (2019) and Mauro et al. (2020)
completed prospective studies, while Le et al. (2019) conducted a retrospective study. Konjeti et
al. and Le et al. looked at the effects of telemedicine on liver transplant patients. Mauro et al.
investigated telemedicine consultations and patient satisfaction. Finally, the studies by Mazzotti
et al. (2018) and Su et al. (2018) were cohort studies that looked at the effects of telemedicine on
patients with liver disease.
The second limitation was the variations in sample sizes. Three studies had small sample
sizes, which could have affected the internal and external validity of the studies (Barnet et al.,
2020; Javanmardifard et al., 2017; Le et al., 2019). On the contrary, four studies had large sample
sizes (Konjeti et al., 2019; Mauro et al., 2020; Mazotti et al., 2018; Su et al., 2018). Due to the
larger sample size, the strength of evidence is reliable and generalizable.
Third, the duration of the studies also varied, between 12 weeks to four years. The short
study duration limited the reliability of the results. Longer study duration is needed to find strong
evidence regarding the use of telemedicine in CLD. Despite these limitations, the literature
review indicated that telemedicine is an effective intervention for health promotion.
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Conclusion
Despite the heterogeneity and the limited number of studies, this literature review
concluded that telemedicine could enhance patient access to care, improve clinical outcomes, and
increase patient satisfaction. Interventions found to be effective were nutritional counseling,
lifestyle modifications, and provider consultation and follow-up. However, the evidence
presented in this literature review is limited, and further studies are required to examine its
effects on managing patients with chronic liver disease. Studies with rigorous designs and larger
sample sizes are needed to better evaluate the effectiveness of telemedicine.
Project Model and Supporting Framework
A Model for Change to Evidence-Based Practice is a systematic process of implementing
change in health care (Rosswurm & Larrabee, 2007). This framework incorporates change theory
and can guide practitioners in the process of evidence-based change. This DNP project utilized
this model for change to be adapted in an ambulatory setting (see Appendix C for Project
Model).
Based on the National Health Interview Survey collected from 2013 through 2017,
patients with chronic liver disease face barriers related to appointments, access to care, and
finances at higher rates than patients with other diseases (Wong et al., 2019). Barriers to care can
negatively impact the patient’s ability to meet their needs, putting them at a higher risk of
developing complications. To address these barriers, changes in current practice are needed to
improve the quality of care and patient outcomes. Based on evidence gathered from the literature
review, a telemedicine protocol involving a multi-disciplinary team can optimize care for
patients awaiting liver transplantation with non-alcoholic steatohepatitis. Traditional practice is
geared towards in-office appointments for a consultation or follow-up. Telemedicine is an
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excellent alternative to traditional practice. It increases access to care without compromising the
quality of care provided.
A Plan-Do-Study-Act or PDSA model for improvement was used as the supporting
framework for this DNP project (Hickey & Brosnan, 2017). It provided a guide to develop, test,
implement, and evaluate outcomes from the proposed changes (see Appendix D for an Adapted
PDSA Model for Improvement). The PDSA model was incorporated in step four – designing
practice change, and step five – implement and evaluate the change in practice of the Model of
Evidence-Based Practice Change.
Organizational Analysis
This DNP project was implemented at Keck Medicine of USC’s Transplant Institute in
Los Angeles, California. Keck Medicine of USC (2020) is a non-profit, private academic health
system that consists of three hospitals (Keck Hospital of USC, USC Norris Cancer Hospital, and
USC Verdugo Hills Hospital) and forty multispecialty clinics throughout Southern California.
The main facility sits in the heart of Los Angeles. It primarily services the indigent, medically
underserved, and minority populations of the Los Angeles community. Keck Hospital of USC,
which has 401 acute beds, is where the transplants are performed. The health system has one
gastroenterology and hepatology clinic, one transplant clinic, and one outreach clinic for both
services.
Thirty-six percent of the university’s operating revenue is from the health system
(University of Southern California, 2019). In 2019, $1.89 billion was the total health care
services revenue. The impact of COVID-19 on the university has led to cost-cutting measures,
including salary cuts, hiring freeze, and discontinuation of non-essential projects. However,
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during the pandemic, the institute continued to perform transplants, generating revenue for the
university.
The USC Transplant Institute has four solid organ transplant programs – heart, kidney,
liver, and lung. Approximately two-thirds of the revenue comes from the transplant event and
cost report and about one-third from downstream income (Cost Report Data, 2020). Other
sources of income are reimbursement, supplemental payment, and other remuneration directly
from the hospital after the transplant. The kidney program has the highest case volume and
generates the most revenue of all the programs. The current budgets allocated for Keck Medicine
of USC’s Transplant Institute and the Department of Gastroenterology and Hepatology
department are not published.
An organizational readiness to change assessment was used to analyze the organization
(Helfrich et al., 2009). The key findings of this assessment were:
1. The university and leaders of the organization support current practice changes
leading to quality care.
2. Staff members are willing to participate in changes to improve patient care.
3. Clinical management provides project feedback and suggestions for improvement.
4. No financial support can be obtained due to the impact of COVID-19 on the
institution.
5. Grants/financial support from foundations can be obtained to support quality
improvement and research projects.
Strengths, Weaknesses, Opportunities, Threats Analysis
An analysis of Keck Medicine of USC’s strengths, weaknesses, opportunities, and threats
was made to aid in the strategic planning for this DNP project. Ranked #18 best hospital in the
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United States, Keck Medicine of USC is one of the top-performing health systems nationwide
(U.S. News & World Report, 2020). The institution prides itself on health care excellence,
clinical care, teaching, and research. The COVID-19 pandemic affected the institution
financially, leading to cost-cutting measures, consistent staffing shortages, a high turnover rate,
and lower employee satisfaction. The institution recognizes its weaknesses and is aware of the
opportunities for improvement.
In 2021, the liver transplant program at Keck Medicine of USC became the largest liver
transplant program in California and the West Coast. The program is now the fourth largest liver
transplant program in the nation. In addition, the USC Transplant Institute ranked second in the
country for combined heart and liver transplants.
Project Goal and Aims
The goal of this DNP project was to develop a telemedicine protocol optimize the
delivery of care among patients with NASH. The aims of this project were:
1. To develop a telemedicine protocol to be incorporated into the department’s care
model for patients with chronic liver disease.
2. To implement and evaluate the protocol.
3. To make recommendations for sustainability and scaling to a broader population of
individuals awaiting organ transplantation within the organization and as a model
protocol for other transplant centers.
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Chapter 3
Methods
This quality improvement project developed a telemedicine protocol to be incorporated
into the Liver Transplant Department’s care model. The protocol included a monthly
telemedicine appointment with patients by a multi-disciplinary team. This project aimed to
address the patients’ needs, reduce hospitalizations, improve patient outcomes, improve quality
of life, increase patient satisfaction, and reduce health care costs.
Aim 1: To develop a telemedicine protocol to be incorporated into the department’s care model
for patients with chronic liver disease.
The protocol consisted of a monthly telemedicine appointment for patients with NASH.
The steps followed to create this protocol include:
•

Built a multi-disciplinary team that will follow the patients. A multi-disciplinary
team that would follow the patients was formed. This team included a Transplant
Hepatologist (MD), a Transplant Surgeon (MD), a Transplant Nurse Practitioner
(NP), and Transplant Registered Dietitian (RD).

•

Outlined clinic format. The patient was seen by a physician or a nurse practitioner
once a month for two consecutive months. The physician and the nurse practitioner
alternated seeing the patients each month. The appointment was approximately 20-30
minutes with the providers. In addition, the patient had a 20–30-minute appointment
with the registered dietitian for two consecutive months.

•

Planned for deviation. The patient/s were seen in person for any urgent matters or
per patient request. If a patient was seen in person instead of telemedicine, the multi-
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disciplinary team followed the protocol and continued to provide routine care, as they
would via telemedicine.
•

Set goals, roles, expectations, training, and evaluation. The MD/NP partnered with
the RD for each telemedicine appointment. The MD/NP and RD made personalized
recommendations to each patient depending on their need/s. Training for the MD, NP,
and RD were provided. Training included educational sessions regarding the
telemedicine protocol, how to use the InTouch telemedicine platform, what questions
to ask the patient during the appointment, forms to use during the appointment, what
data to collect on each appointment, and what to do when there was a need to deviate
from the telemedicine protocol. Evaluation of the telemedicine protocol was done on
a monthly basis.

•

Materials. This DNP project was awarded a Clinical Scientific Research Grant from
the OneLegacy Foundation for $55,000. Through this funding, the patients were
provided the following:
1. A tablet device to ensure that they had the technological means to participate in
telemedicine appointments.
2. A weighing scale to track the progress of their weight loss/gain journey.
3. A food and activity journal for the purpose of tracking their weight, dietary habits,
and physical activity.
4. A digital hand dynamometer to track handgrip strength as part of the frailty
evaluation.
Other funding was used for flyers, consents, patient handouts, and patient
forms/questionnaires needed for this project.
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•

Selected a telemedicine platform. Keck Medicine of USC supports the InTouch
telemedicine platform. The physicians, NP, and RD utilized the InTouch platform to
conduct the telemedicine appointments. Training and handout were provided to each
patient on accessing the appointment using the tablet. Keck Medicine of USC’s
Information Technology Department is available to aid the patient in troubleshooting.

•

Outlined the patient selection process. Keck Medicine of USC’s liver transplant
program has a waitlist list mortality rate of 10.7% compared to the national waitlist
mortality rate of 8.6% for liver transplant. Among patients with CLD, liver transplant
candidates with NASH have higher rates of morbidity and mortality. This
telemedicine protocol only included patients with decompensated liver disease,
diagnosis of NASH, and undergoing transplant evaluation or awaiting a liver
transplant. All patients need to sign a consent and agree to participate in a monthly
telemedicine appointment with the MD/NP and RD. The patients must have access to
the internet. The connection can be anywhere where the patient can access the
internet, i.e., home, family, or friend’s house. Exclusion criteria are patients with
hepatocellular carcinoma, other cancer, on hemodialysis, undergoing evaluation or
listed for dual-organ transplant, and previously transplanted. The selection of patients
is through assessment, OTTR database search, and chart review.

•

Gathered available patient data. The following information were obtained via chart
review: demographics, diagnosis, Child-Turcotte-Pugh score, MELD-Na score,
hospitalization rates, urgent care/ED utilization, complications from liver disease,
weight, and sarcopenia status.
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•

Planned intervention. The standard of care was provided to the patients during the
telemedicine visits. The multi-disciplinary team provided personalized nutritional
recommendations and physical activity prescription to all patients. Frail patients were
recommended to outpatient physical therapy for evaluation and treatment, if
determined necessary by the provider and dietitian.

•

Presented the protocol for review and approval. The telemedicine protocol was
presented for review and approval by the project review/approving committee.
The protocol was also reviewed by the USC’s Institutional Review Board (IRB). The
protocol was revised per the IRB recommendations. The final protocol was approved
on January 4, 2022.

Aim 2: To implement and evaluate the protocol.
Implementation. The project was implemented immediately after IRB approval.
•

Obtained baseline information. Baseline patient information was obtained,
including the Chronic Liver Disease Questionnaire (CLDQ), the Liver Disease
Undernutrition Screening Tool (LDUST), and the Short-Form Patient Satisfaction
Questionnaire (PSQ-18).
1. Chronic Liver Disease Questionnaire (CLDQ) is a liver disease-specific healthrelated quality of life instrument developed to address fatigue, activity, emotional
function, abdominal and systemic symptoms, and worry (Younossi et al., 1999). It
is used to correlate the domains with the severity of the patient’s liver disease. See
Appendix E for the Chronic Liver Disease Questionnaire.
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2. Liver Disease Undernutrition Screening Tool (LDUST) is used to detect
undernutrition in patients with cirrhosis (Casas Deza et al., 2021; McFarlane et
al., 2018). See Appendix F for the Liver Disease Undernutrition Screening Tool.
3. The Short-Form Patient Satisfaction Questionnaire (PSQ-18) is a tool that
assesses patient satisfaction and can be applied to various settings (Marshall &
Hays, 1994; Thayaparan & Mahdi, 2013). See Appendix G for The Short-Form
Patient Satisfaction Questionnaire (PSQ-18).
•

Assessed the patient on each appointment.
-

The MD/NP addressed the following on each appointment: the patient’s wellbeing, any significant events related to their health since their last appointments,
such as signs/symptoms, medication issues, urgent care/emergency department
(ED) visits, hospitalizations, and any changes on their health condition. The
MD/NP gave the patient and/or their family members advice on managing their
condition.

-

Nutritional recommendations were directed by a registered dietitian who is
familiar with the nutritional needs of patients with cirrhosis. The RD used the
LDUST to assess the patient’s dietary habits, weight loss/gain, and
exercise/activity level. At each appointment, the RD addressed the patient’s
behavior, weight loss/gain, and exercise/activity level on each appointment.
Nutritional counseling and nutritional education were also provided. In addition,
the RD made recommendations on the use of supplements when necessary.

•

Family members and/or caregivers were encouraged to participate in the
telemedicine appointments. Good social support is a requirement for patients
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awaiting organ transplantation. Although it is not required for the patient’s family
members and/or caregivers to be present in their appointments, they were highly
encouraged to participate in the patient’s care.
•

The multi-disciplinary team collaborated to make recommendations. The multidisciplinary team collaborated on the patient’s care. For example, if the Registered
Dietitian determined that the patient could benefit from supplements, the physician or
the nurse practitioner could prescribe the supplements as recommended. The team
decided on the plan of care and target goals for the next appointment. At the end of
each appointment, both the MD/NP and RD educated and reinforced information to
the patient and their family members.

•

Recordkeeping. All information collected at each appointment was documented in
the patient’s chart. In addition, a project was created in the REDCap database to store
monthly data for each patient. A HIPAA compliant spreadsheet was maintained for
ease of data comparison. All identifying information was omitted from the
spreadsheet. Instead, each patient was assigned a number, from one to twenty, for
ease of tracking and inputting data. All documents were stored in a secured cloud
drive at Keck Hospital of USC.

•

Evaluation. To ensure that the protocol was implemented correctly, the multidisciplinary team met biweekly and as needed to discuss any issues.

•

Chart audit. Every month, a chart audit was done to ensure that all necessary
information was collected on the telemedicine appointment. An ongoing analysis of
the data collected at each appointment was done using the Excel spreadsheet. This
helped the multi-disciplinary team track any changes in the patient’s health. For
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example, weight changes were analyzed based on the weight measurement gathered
at each appointment. To support sustainability and scaling, data collection continued
after the six months of telemedicine.
•

Questionnaire. The patients completed the CLDQ and LDUST at the first visit and
each subsequent telemedicine appointment. The patients will complete six CLDQ and
LDUST by the end of the telemedicine protocol. In addition, the patients included in
the study completed the PSQ-18 questionnaire at the first visit. At the end of the sixth
visit, the patient will need to complete the PSQ-18.

•

Analysis. Data was analyzed to evaluate the efficacy of a monthly telemedicine
appointments on weight, BMI, emergency department visits, hospitalizations,
physical activity level, liver-disease related quality of life, malnutrition, MELD-Na
score, and frailty status. The changes in weight and BMI were assessed using a lefttailed t-test. The changes in MELD-Na scores, hospitalization rates, emergency
department and urgent care utilization, Chronic Liver Disease Questionnaire domains,
Liver Disease Undernutrition Screening Tool score, Liver Frailty Index score, and
physical activity level were analyzed using a paired sample t-test.

Aim 3: To make recommendations for sustainability and scaling to a broader population of
individuals awaiting organ transplantation within the organization and as a model protocol for
other transplant centers.
•

Presentation of the project at USC. The telemedicine project was presented at
the USC Liver WIP Conference and to the Keck Medicine of USC’s Quality
Committee of the Hospital Governing Board. The project goals and progress were
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provided to the audience. The project will also be presented at the USC Transplant
Hepatology Core Lecture at the end of April.
•

Magnet Redesignation. The telemedicine project, the mentorship from Dr.
Annette Sy, and the leadership immersion will be included in the application for
Magnet Redesignation.

•

Report to the OneLegacy Foundation. After analyzing the baseline to end of
protocol data, a final report will be prepared for the OneLegacy Foundation. This
will discuss all findings from the quality improvement project, including the
patients’ clinical outcomes, quality of life based on the CLDQ, and patient
satisfaction based on PSQ-18. A comparison will be made between data from the
past two years and outcomes from the quality improvement project.

•

Presentation of outcomes at Keck Medicine of USC. The benefits of
telemedicine on system goals such as cost, no-show rates, patient satisfaction,
ED/urgent care utilization, hospitalization, and re-admission rates will be
presented to the project review/approving committee, GI and Transplant
Department Physicians, Nurse Practitioners, Registered Dietitians, and other staff
members. In addition, the outcomes will be presented to the hospital
administration, including Keck Hospital of USC’s Chief Executive Officer, Rod
Hanners, MD, and Chief Nursing Officer, Annette Sy, RN. As a part of the
presentations of outcomes, it will also be explained that data collection is
continuing. Arrangements will be made for a subsequent report of outcomes,
including any updating of recommendations. Telemedicine to optimize the
delivery of care can drive improvement in clinical outcomes, patient retention,
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key performance indicators, and metrics that lead to greater reimbursements and
incentive payments.
Dissemination
Conference presentation. An abstract will be submitted for oral or poster presentation at
the American Association for the Study of Liver Diseases’ The Liver Meeting, the
International Liver Transplantation Society’s ILTS Annual Congress, and Sigma Theta
Tau’s International Nursing Research Congress. If selected, findings will be presented at
national conferences. Other transplant centers can utilize the outcomes of this quality
improvement project to improve patient care.
Publishing results. A manuscript will be submitted to the American Journal of
Transplantation in early 2023.
Business Implications
Patients with NASH awaiting liver transplantation are at high risk of developing
complications that lead to higher health care utilization and mortality rates. They have higher
rates of poor health, barriers to care, and poor health-related quality of life. Improving clinical
outcomes for liver transplant candidates with NASH remains a challenge nationally.
Telemedicine can reduce the quality gaps and overcome barriers to care. It offers various
advantages, including enhancing access to care, improving clinical management, enhancing
communication between patients and providers, increasing patient satisfaction, improving patient
outcomes, and reducing health care costs. It also benefits the system by reducing costs,
increasing patient retention, and improving key performance indicators and metrics.
The projected outcomes of this quality improvement initiative are:
1. Improvement in clinical outcomes
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2. Increase in quality of care and patient satisfaction, and
3. Improvement in metrics and reduced health care costs leading to higher revenue.
Human Subjects
This DNP project was reviewed by the Yale Institutional Review Board (IRB) and
affirmed that this was a quality improvement project. However, the University of Southern
California (USC) IRB required an application and approval for the protection of human subjects
under 45 CFR 45.111. The USC IRB also required that all participants sign a written consent.
The project was approved by the IRB on January 4, 2022.
Timeline
See Appendix H for GANNT Chart – Telemedicine Timeline.
Immersion Plan
The American Association of Colleges of Nursing DNP Essentials (2006), leadership
knowledge and skills learned at the Yale School of Nursing were put into practice during the
leadership immersion. Dr. Annette Sy, Keck Medicine of USC’s Chief Nurse Executive, was
identified as the external expert and mentor for this DNP project.
After the defense and approval of the project at Yale, the telemedicine protocol was
approved by the USC project committee. Through Dr. Sy’s guidance and USC Transplant
Institute’s support, the DNP project implementation began immediately after IRB approval.
A monthly immersion log and project summary were submitted to Dr. Sy and the Yale
School of Nursing faculty to provide a project update. Multiple meetings with the external
mentor were held via Zoom to discuss project trajectory, identify issues surrounding the project
development and implementation, and evaluate preliminary outcomes.
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Chapter 4
Results
For this paper, only the ten patients that completed visits 1 and 2 were included in the
analysis. The results compared the visit 1 and visit 2 outcomes. The JMP Statistical Software, a
subsidiary of SAS Institute, was the tool utilized (JMP®, Version Pro 16. SAS Institute Inc.,
Cary, NC, 1989–2021).
Weight
Between visits 1 and 2, there was a total 21.319 kg weight loss. A left-tailed t-test was
conducted to compare the weight loss between visits 1 and 2. The median weight decreased from
95.6 kg on visit 1 to 89.21 kg on visit 2. The observed mean difference was -2.1319, 95% CI [4.4591, 0.19528]. Weight loss after the telemedicine protocol implementation was statistically
significant (t-test -2.07234, p = 0.0341). The graph in Figure 1 shows the mean weights, the
mean differences between weights, the mean difference depicted in a solid red line, and the upper
and lower confidence interval (CI) for the mean difference depicted in red dashed lines. See
Figure 1 for Weight Changes.
BMI
A left-tailed t-test was conducted to compare BMI differences between visits 1 and 2. The
total decrease in BMI among the patients was 8.05 kg/m2. The median BMI decreased from
36.44 kg/m2 on visit 1 to 34.565 kg/m2 on visit 2. The observed mean difference was –0.805,
95% CI [-1.6853, 0.07544]. After the telemedicine protocol implementation, the changes in BMI
were statistically significant (t-test -2.06858, p = 0.0343). Figure 2 shows the mean BMI, the
mean differences between BMIs, the mean difference depicted in a solid red line, and the upper
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and lower confidence interval for the mean difference shown in red dashed lines. See Figure 2
for BMI Changes.
MELD-Na Score
The median MELD-Na score on the patients was 11 on visit 1 and 12 on visit 2. A paired
t-test was used to analyze the MELD-Na score. There was no statistically significant finding (tvalue = 0.309426, p-value = 0.7640) on the patient’s MELD-Na score changes.
Hospitalization Rates
The average liver-related hospitalization (LRH) rate on visit 1 was 1.1 hospitalizations
and zero on visit 2. Only one patient was hospitalized due to liver disease on visit 2. A paired ttest was conducted to compare the hospitalizations rates. After the telemedicine protocol
implementation, the changes in LRH were statistically significant (t = -2.53546, p = 0.0319).
Between visits 1 and 2, the observed mean difference was –1, 95% CI [-1.8922, -0.1078]. Figure
3 shows the mean LRH, the mean differences between LRH, the mean difference (solid red line),
and the confidence interval for the mean difference (red dashed lines). See Figure 3 for LiverRelated Hospitalization Changes. The range of the differences is greater than half the range of
the data, as depicted by the diamond shape on the figure.
For hospitalizations not due to liver disease, there were three hospitalizations on visit 1
and zero on visit 2. A paired t-test was done to compare the difference between the non-liver
hospitalizations. The outcome was not statistically significant (t = -1.40556, p = 0.1934).
Emergency Department and Urgent Care Utilization
There was no liver-related ED utilization between visits 1 and 2. For ED visits not related
to liver disease, there were four ED utilizations on visit 1 and zero on visit 2. The outcome was
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statistically significant using a paired t-test (t = -2.44949, p = 0.0368). No patients went to an
urgent care facility from visits 1 and 2.
Chronic Liver Disease Questionnaire
The Chronic Liver Disease Questionnaire has six domains: abdominal symptoms (AS),
fatigue (FA), systemic symptoms (SS), activity (AC), emotional function (EF), and worry (WO).
A paired t-test was conducted to analyze the CLDQ overall score and each domain. The overall
median score was 4.74 on visit 1 and 4.665 on visit 2. The overall CLDQ score was not
statistically significant (t = 0.079851, p = 0.9381). See Table 1 for Comparison of Visits 1 and 2
CLDQ Outcomes in Mean ± SD by Domain for the differences in each domain mean scores with
standard deviation between visits 1 and 2.
Abdominal Symptoms
The abdominal symptoms median score was 5.665 on visit 1 and 5 on visit 2. There was
no statistical significance noted in the abdominal symptoms’ domain (t = 0.689113, p = 0.5081).
Fatigue
The fatigue median score was 5 on visit 1 and 4.5 on visit 2. There was no statistical
significance noted in the fatigue domain (t = 0.0475, p = 0.9632).
Systemic Symptoms
The systemic symptoms median score was 5.1 on visit 1 and 4.8 on visit 2. No statistical
significance was noted in the systemic symptoms’ domain (t = -0.19108, p = 0.8527).
Activity
The activity domain median score was 4.5 on visit 1 and 5.996 on visit 2. The change in
the activity was statistically significant (t = 2.957929, p = 0.0160). The observed mean difference
was 1.101, 95% CI [0.25898, 1.94302]. Figure 4 shows the mean CLDQ activity score, the mean
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differences between the activity scores, the mean difference (solid red line), and the CI for the
mean difference (red dashed lines). See Figure 4 Changes in the CLDQ Activity Domain.
Emotional Function
The median score for the emotional function was 5 on visit 1 and 5.37 on visit 2. There
was no statistical significance noted (t = 0.105927, p = 0.9180).
Worry
The worry median score was 3.9 on visit 1 and 3.3 on visit 2. After the telemedicine
protocol implementation, the changes in the worry domain were statistically significant (t = 2.660532, p = 0.0260). The observed mean difference was -0.76, 95% CI [-1.4062, -0.1138]. The
graph in Figure 5 shows the mean CLDQ worry score, the mean differences between the worry
scores, the mean difference depicted in a solid red line, and the confidence interval for the mean
difference displayed in red dashed lines. See Figure 5 Changes in the CLDQ Worry Domain.
Liver Disease Undernutrition Screening Tool
There was no malnutrition finding between visits 1 and 2. There were no statistically
significant changes noted in the patients’ nutritional status.
Liver Frailty Index
The median LFI decreased from 4.35 (pre-frail) on visit 1 to 4.265 (pre-frail) on visit 2.
The changes were analyzed using paired t-test. There was no statistically significance noted (t = 1.6403, p = 0.1353).
Physical Activity
The medial physical activity level of patients remained at moderate (level 2) between
visits 1 and 2. Using a paired t-test, the result was analyzed, and no statistical significance was
noted in the physical activity level of the patients.

27

Chapter 5
Discussion
The USC IRB approved the telemedicine protocol in January 2022. Due to the surges in
the COVID-19 pandemic, the implementation of the project was delayed, affecting the project’s
timeline. The preliminary findings presented in this paper included the outcomes from ten
patients that completed visits 1 and 2. See Figure 6 for Comparison of Visits 1 and 2 Outcomes.
The findings of this DNP project suggested that the use of telemedicine to deliver the
standard of care improves patient outcomes. The analysis showed that the intervention
effectively promoted weight loss, decreased hospitalizations and ED utilization, improved patient
activity levels, and lessened the patients’ worry. In addition, there were no changes that indicated
worsening frailty, malnutrition, abdominal symptoms, fatigue, systemic symptoms, emotional
function, and MELD-Na score.
The significant weight loss and BMI reduction correlated with the patients’ reported
increase in the physical activity domain of the CLDQ. This observed improvement was similar to
other telemedicine studies (Barnett et al., 2020; Javanmardifard et al., 2017; Mazzotti et al.,
2018). In contrast, the measured physical activity based on the RD assessment showed the
patients’ physical activity level remained moderate between visits 1 and 2.
The lack of improvement in physical activity can be due to the patients’ frailty status and
fatigue level. Between visits 1 and 2, the patients reported the same fatigue level on the CLDQ.
This could have prevented the patients from increasing their activity level. In addition, the Liver
Frailty Index assessment showed that, on average, the patients are pre-frail. The patients
identified to be frail were referred for outpatient physical therapy evaluation and treatment.
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Despite the frailty level decreasing from 4.35 to 4.265, there were no statistically significant
findings to suggest an improvement in the paired t-test analysis.
One patient had refractory ascites and underwent weekly paracentesis. The patients’
volume status could have contributed to the decrease in weight and BMI. However, the total
weight loss of 21.319 kg among the ten participants is likely because the patients have
maintained their physical activity level and adhered to the nutritional recommendations
prescribed by the multi-disciplinary team.
All patients were instructed to follow a two-gram low salt, high protein diet. For patients
with diabetes mellitus, a low carbohydrate diet was added to their nutritional prescription. The
RD did not identify any patients in need of a nutritional supplement. The patients’ nutritional
status and abdominal symptoms did not change between visits 1 and 2. However, in similar
studies done by Barnett et al. (2020) and Javanmardifard et al. (2017), there was a statistically
significant increase in the patients’ nutritional status. The difference between the studies and this
project was the frequency of follow-ups with the patients. For this project, the RD followed the
patients once a month, whereas the telemedicine studies by Barnett et al. and Javanmardifard et
al. provided a weekly follow-up with patients.
There were no liver-related ED and urgent care visits. However, there was one liverrelated hospitalization due to hepatic encephalopathy. This is a significant finding, decreasing the
LRH rate from 1.1 to zero. In addition, there were no significant changes noted in the patients’
MELD-Na score. This finding is likely due to the frequency of follow-ups with patients. A
similar study by Su et al. (2018) suggested that telemedicine helped address liver-related issues
and improved patient care, which led to higher survival rates.
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A higher CLDQ score is linked with an improved health-related quality of life (Chawla et
al., 2016; Younossi et al., 1999). The CLDQ worry domain analysis was statistically significant.
However, the difference in the domain score was 0.6 between visit 1 and visit 2, indicating that
the patients were slightly more worried on visit 2 than visit 1. Moreover, the emotional symptom
domain increased from 5 on visit 1 to 5.37 on visit 2, indicating that the patients experienced an
improvement in their emotional wellbeing on visit 2. On the contrary, the paired t-test analysis
found no statistical significance between the scores. The overall CLDQ findings showed no
significant improvements in the patients’ quality of life. This can be due to the short interval
between data collection.
Limitations
The first limitation of this DNP project is the small sample size. Due to the delay in
implementation, only ten patients completed visits 1 and 2 by February 28, 2022. All analyses
were performed using a paired t-test. The small sample size can make no difference between
visits 1 and 2 variables and contribute to a type II error.
The second limitation is the short study duration. In the preliminary analysis of this DNP
project, data from visits 1 and 2 were included. However, differences may show with a longer
study duration. A shorter study duration may not yield reliable results.
The last limitation of this project is the generalizability. This project was conducted at
one transplant center and limited the population to patients with NASH, affecting the project's
external validity. NASH is not representative of the patients with CLD.
Conclusion
In summary, this DNP project revealed that using telemedicine to deliver the standard of
care among patients with NASH can improve patient outcomes. The general findings that
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emerged from this DNP project were: (1) telemedicine can promote weight loss and increase
physical activity, and (2) telemedicine can decrease hospitalization rates and prevent ED/urgent
care utilization. In addition, this project found no significant changes noted in the patients’
MELD-Na score, HRQoL, frailty, and nutritional status.
The preliminary results of this DNP project raise several opportunities for further studies
to evaluate the effects of telemedicine in managing patients with chronic liver disease. A larger
study cohort and longer study duration will be necessary to determine if there is any true
association between telemedicine and improvement in patient outcomes.
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Appendix A

Eligibility

Screening

Identification

Adapted PRISMA Flow Diagram

Records identified through PubMed
database searching
(n = 172)

Records identified through Embase
database searching
(n = 234)

Records after filtering full text availability
(n = 325)

Records excluded
(n = 103)
Short survey: 1
Abstracts: 53
Articles in press: 16
Children: 6
Duplicates: 27

Abstracts screened
(n = 222)
Records excluded (n = 192)
Not focused on liver disease: 113
Not telemedicine: 79
Full-text articles assessed
for eligibility
(n = 30)

Articles excluded (n = 19)
Not evidenced-based,
overview, recommendations
only: 19

Included

Studies screened for relevance
(n = 11)

7 articles included in the
literature review

Articles excluded (n = 4)
Focused on multiple
disease including liver: 2
Limited data provided on
the paper: 2

Appendix A Flow diagram to show number of studies remaining at each stage of literature review.
Source: From Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group. (2009).
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement.
PLOS Medicine, 6(7), e1000097. https://www.doi.org/10.1371/journal.pmed.1000097.
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Appendix B
Evidence Table
Title, authors,
date, journal

Purpose

Level of
Evidence

Sample

Design

Results

Strengths

Liver
Transplant
Recipients’
Experiences
and
Perspectives of
a TelehealthDelivered
Lifestyle
Programme: A
Qualitative
Study

To assess
the
feasibility
of a 12week
telehealth
lifestyle
program

2b*

19
patients
were
included
in the
study,
between
25-68
years old.
63% were
males.

Qualitative
study

Median
attendance was
10 sessions.

Use of focus
groups and
interviews
for data
collection

Amandine
Barnett,
Katrina L.
Campbell,
Hannah L.
Mayr, Shelley
E. Keating,
Graeme A.
Macdonald,
and Ingrid J.
Hickman
2020

To assess
the
experiences
of liver
transplant
recipients
with
telehealth

Focus groups
and one on
one
interviews
were
conducted on
the
participants

Telehealth was
a wellaccepted
experience by
many
participants
(n=8).

It included
data
triangulation
and use of
multidisciplinary
The program The overall
Median
team to
time since is a 12-week experience was develop
telehealth
that lifestyle
liver
schedule and
transplant intervention
interventions
interpret
which
was 4.4
sessions were
results
included
years.
as good or
weekly group better than
Telehealth
Exclusion contact
traditional
lessened the
face-to-face
criteria:
alternating
burden of the
food
education on appointments. participants
allergy or diet and
to travel.
dietary
physical
Telehealth was
restriction activity
advantageous
that would recommendat due to less
44

Weaknesses Contribution:
Science and/or
Practice
Small
Telehealth is
sample size feasible for
lifestyle
There was a modification
probably of programs,
bias from
especially for
the
liver transplant
exclusion of recipients.
participants
without
video
enabled
devices and
non-English
speakers

Journal of
Telemedicine
and Telecare

affect the
MedDiet
eating
pattern,
physical
disability
where
increase in
physical
activity
would be
inappropri
ate,
deemed
unsafe by
the
providers
to
participate
, and nonEnglish
speaker or
unable to
read/write
in
English.

ions, totaling
of 14
telehealth
appointments
(6 dietetic
and 8
exercise
sessions
provided by
dietitians and
exercise
physiologists
.

burden on
travel or to
make
appointments.
Modification
of nutritional
habits was a
positive
experience for
the participants
(n=13).

There was an
Experiences, increase in the
perspectives amount of selfdirected
and
feasibility
physical
activity and
were
awareness of
assessed at
the end of the exercise
capabilities
12-week
and desire to
telehealth
intervention. engage in
healthy
behaviors.

*Oxford Centre for Evidence-Based Medicine: Levels of Evidence (2009)
1a: SR (with homogeneity*) of RCTs, 1b Individual RCT (with narrow Confidence Interval), 1c: All or none, 2a: SR (with homogeneity) of cohort studies, 2b:
Individual cohort study, 2c: “Outcomes” Research; Ecological studies, 3a: SR (with homogeneity) of case-control studies, 3b: Individual Case-Control Study, 4:
Case-series (and poor quality cohort and case-control studies), 5: Expert opinion without explicit critical appraisal, or based on physiology, bench research or
“first principles”
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Title, authors,
date, journal

Purpose

Level of
Evidence

The Effect of
Telenursing on
Self-efficacy in
Patients with
Non-Alcoholic
Fatty Liver
Disease: A
Randomized
Controlled
Clinical Trial

To
determine
the impact
of
telenursing
on
nutritional
behavior
and
physical
activity
selfefficacy

1b*

Sorur
Javanmardifard
, Fariba
Ghodsbin,
Mohammad
Javan Kaviani,
and Iran
Jahanbin
2017
Gastroenterolo
gy and
Hepatology
From Bed to
Bench

Sample

Design

Results

Weaknesses Contribution:
Science and/or
Practice
60
Randomized The reported
The study
Small
Findings of this
participant controlled
mean score of
concluded
sample size. study can be
s were
trial.
both nutritional that
applied in
included
and physical
telenursing
Short length practice to
in the
Sherer and
behavior selfcould
of study.
improve
study. 30
efficacy
improve the
outcomes for
Maddux’s
were
increased in
patient’s self- The study
patients with
nutritional
assigned
behavior
both groups
efficacy in
did not
non-alcoholic
to the
self-efficacy after the
adherence to address its
fatty liver
interventi questionnaire intervention
nutritional
limitations. disease.
on group
regimen and
and Pender’s (p<0.001).
and 30 to
physical
physical
the control activity self- The nutritional activity and
group.
mode was
health
efficacy
questionnaire statistically
behaviors
significant
associated
26.7%
were
(p<0.001) for
with non(n=8)
obtained as
were
baseline
the
alcoholic
fatty liver
females
information. intervention
disease by
and 73.3%
group but not
A nutritionist for the control increasing
(n=22)
awareness.
consulted
were
group
males in
with all the
(p>0.05).
participants.
the
interventi Each got a
on group. written
dietary
20.7%
advice and
were
(n=6)
were
instructed to
46

Strengths

females
and 79.3%
(n=23)
were
males in
the control
group.
Mean age
was 40.3
and 38.3
years in
the
interventi
on and
control
groups.

perform at
least 30 min
of moderate
physical
activity 4-5
times per
week. A
training
booklet was
provided.
The
intervention
group had
telephone
follow-ups
for 12 weeks
in which
adherence to
diet and
physical
activity were
assessed.
The control
group did not
receive any
interventions.

*Oxford Centre for Evidence-Based Medicine: Levels of Evidence (2009)
1a: SR (with homogeneity*) of RCTs, 1b Individual RCT (with narrow Confidence Interval), 1c: All or none, 2a: SR (with homogeneity) of cohort studies, 2b:
Individual cohort study, 2c: “Outcomes” Research; Ecological studies, 3a: SR (with homogeneity) of case-control studies, 3b: Individual Case-Control Study, 4:
Case-series (and poor quality cohort and case-control studies), 5: Expert opinion without explicit critical appraisal, or based on physiology, bench research or
“first principles
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Title, authors,
date, journal

Purpose

Level of
Evidence

Sample

Design

Results

TelehealthBased
Evaluation
Identifies
Patients Who
Are Not
Candidates for
Liver
Transplantation

To
compare
transplant
evaluation
outcomes
between
referrals
triaged
through
SCANECHO
with direct
referrals

2a*

190
patients
were
referred
for
transplant.
91 were
referred
through
the
SCANECHO
program
(47.8%).

Patients
referred for
liver
transplant
evaluation
were either
referred to
SCANECHO for a
preliminary
analysis of
candidacy
before
completing a
full work-up
or direct
referrals for
fullevaluation.

Patients
referred
through
SCAN-ECHO
were likely to
be candidates
for
transplantation
during the
initial referral.

Venkata Rajesh
Konjeti,
Douglas
Heuman,
Jasmohan S.
Bajaj,
HoChong
Gilles, Michael
Fuchs, Phillips
Tarkington,
and Binu V.
John
2019
Clinical
Gastroenterolo
gy and
Hepatology

Majority
were male
and
Caucasian
in both
groups.
Mean age
for both
SCANECHO
and nonSCANECHO

The study
included all
liver
transplant
referrals
between
August 2012
and
September
2016 at a
48

Telehealthbased triage
reduced
unnecessary
transplant
evaluations by
60%.
This program
promoted
identification
of
noncandidates
effectively,
minimized
unnecessary
testing, travel,
and reduced
cost.

Strengths

Weaknesses Contribution:
Science and/or
Practice
Good sample The study
Findings of this
size
was limited study suggests
to a single
that telehealth is
Collected
VA facility, useful in
data and
which
identifying
clinical
focused on a noncandidates
characteristic unique
for
s of patients
population
transplantation
referred for
without the
liver
Generalizab need for
transplantatio ility of the
additional
n
findings
testing.
may be
Compared
constrained It can improve
the
due to the
access, reduce
cost and
characteristic limitations
minimize
s of the
above.
SCANunnecessary
ECHO group
testing.
and nonSCANECHO group
including the
indication for
transplant,
rejection
rates, and
reasons for
non-

group was
60.

single VA
center.

Rejection at
time of
transplant
referral was
higher among
non-SCANECHO group
(41.4%)
compared to
the SCANECHO group
(p<0.0001).
Rejection after
completing
evaluation
work-up was
higher among
non-SCANECHO group
(55.6%)
compared to
the SCANECHO group
(23.1%)
(p<0.0001).
Fewer patients
in the SCANECHO group
were denied
for transplant

49

transplant
candidacy

due to
psychosocial
issues,
comorbidities,
and
progression of
HCC.
*Oxford Centre for Evidence-Based Medicine: Levels of Evidence (2009)
1a: SR (with homogeneity*) of RCTs, 1b Individual RCT (with narrow Confidence Interval), 1c: All or none, 2a: SR (with homogeneity) of cohort studies, 2b:
Individual cohort study, 2c: “Outcomes” Research; Ecological studies, 3a: SR (with homogeneity) of case-control studies, 3b: Individual Case-Control Study, 4:
Case-series (and poor quality cohort and case-control studies), 5: Expert opinion without explicit critical appraisal, or based on physiology, bench research or
“first principles
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Title, authors,
date, journal

Purpose

Patient
Satisfaction
and Healthcare
Utilization
Using
Telemedicine
in Liver
Transplant
Recipients

To assess
2a*
the impact
of
telemedicin
e in
overcomin
g barriers
to care
while
sustaining
strong
patientphysician
relationship
s

Long B. Le,
Harman K.
Rahal,
Matthew R.
Viramontes,
Katherine G.
Meneses, Tien
S. Dong, and
Sammy Saab
2019
Digestive
Diseases and
Sciences

Level of
Evidence

Sample

Design

Results

Weaknesses Contribution:
Science and/or
Practice
21 postRetrospectiv The PSQ-18
Control
Small
Findings of this
liver
e study
score did not
patients were sample size study suggests
transplant
differ
used to
that
patients
Patients were significantly
match each
The study
telemedicine
were
divided to
between the
telemedicine found no
contributes to
included
telemedicine groups
patients to
significant
reduced cost
in the
group and
(p=0.89). The
ensure
difference in and less time
telemedici traditional in- lowest mean
adequate
general
off work to
ne study.
office
score for both
responses for patient
make the
follow-up
groups was the 1:1
satisfaction follow-up
group.
dissatisfaction matching, to between
appointment.
Three
patients
with the
maximize the groups.
were used Patient
expenditures
effects of any
as controls Satisfaction
involving
selection
The
for the
Questionnair medical care
bias.
selection
(p=0.03).
study.
e-18 (PSQprocess
Accessibility
18),
could have
Mean age Telemedicine of the visit also
contributed
Satisfaction
had a low
to selection
was 51
Questionnair score (p=0.89).
years for
bias.
e (TSQ), and The highest
the
Patients
was the
telemedici Health
were
Utilization
interpersonal
selected by
ne group
Questionnair manner and
and 52
convenience
friendliness of
e (HUQ)
years for
using
the control were used to the physician
clinical
assess patient perceived
group
profile,
satisfaction
(p=0.32).
(p=0.89).
insurance
and
coverage,
and
51

Strengths

healthcare
utilization.

The TSQ
indicated that
patients in the
Each
telemedicine
telemedicine group had
patient who
moderate to
responded
high level of
with the
satisfaction
questionnaire with
were
telemedicine
matched to a services. 85%
post-liver
of the
transplant
questions had a
control
4 or higher
patient.
score.
The HUQ
mean score
was higher
among the
telemedicine
group. The
highest
satisfaction
was the saved
travel time and
decrease
expenditure
associated with
in-person
appointments.

52

familiarity
and comfort
level with
computers.
Patients
were
matched by
clinical
diagnosis
and age
range.
The use of
survey
contributed
to a degree
of response
bias.

Patient
outcomes did
not differ in
both groups.
*Oxford Centre for Evidence-Based Medicine: Levels of Evidence (2009)
1a: SR (with homogeneity*) of RCTs, 1b Individual RCT (with narrow Confidence Interval), 1c: All or none, 2a: SR (with homogeneity) of cohort studies, 2b:
Individual cohort study, 2c: “Outcomes” Research; Ecological studies, 3a: SR (with homogeneity) of case-control studies, 3b: Individual Case-Control Study, 4:
Case-series (and poor quality cohort and case-control studies), 5: Expert opinion without explicit critical appraisal, or based on physiology, bench research or
“first principles
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Title, authors,
date, journal

Purpose

Telemedicine
Improves
Access to
Hepatology
Consultation
with High
Patient
Satisfaction

To evaluate 2b*
the impact
of
telemedicin
e in
resolving
consultatio
ns

Ezequiel
Mauro,
Sebastian
Marciano,
Maria C.
Torres, Juan D.
Roca, Abel L.
Novillo, and
Adrian Gadano

To assess
patient
satisfaction
by using
telemedicin
e

2020
Journal of
Clinical and
Experimental
Hepatology

Level of
Evidence

Sample

Design

Results

Strengths

200
patients
(n=200)
were
included
to
participate
on the
telemedici
ne
consultati
ons.

This study
provided
telemedicine
consultations
to patients
using nonhepatologist
health care
providers.

73% (n=145)
consultations
were resolved
through
telemedicine.
55 patients
required faceto-face
consultation.

Patient
satisfaction
was assessed
using the
Patient
Satisfaction
Questionnair
e Short Form
(PSQ-18)
and
Telemedicine
Satisfaction
Questionnair
e (TSQ).

A total of 188
patients
answered the
questionnaires.
PSQ-18 results
showed a high
degree of
satisfaction
except for
financing of
the
consultation.
On the other
hand, 70% of
the questions
had the highest
possible score.
TSQ showed a
high degree of
general

Outcomes of
the study
supports the
implementati
on of
telemedicine
to provide
early
consultations
or increase
access to
specialized
consultations
.

Median
age of
patients
was 54.
56% were
males.

54

Weaknesses Contribution:
Science and/or
Practice
Limitation
Findings of this
included
study suggests
possible
that
selection
telemedicine
bias. The
consultations
providers
resulted in high
that
level of patient
provided
satisfaction.
telemedicin
e were the
This study
participating supports the
physicians.
implementation
of telemedicine
Lack of
to provide early
control
consultations or
group
increase access
to specialized
Lack of
consultations.
final
diagnosis
evaluation
or
confirmatio
n made by
the nonhepatologist
providers

satisfaction
with
telemedicine.
Most common
diagnosis
associated with
the resolved
consultations
were nonalcoholic fatty
liver disease,
viral hepatitis,
and benign
liver lesions.
HCC and
cirrhosis were
the common
reasons for
face-to-face
consultations.
*Oxford Centre for Evidence-Based Medicine: Levels of Evidence (2009)
1a: SR (with homogeneity*) of RCTs, 1b Individual RCT (with narrow Confidence Interval), 1c: All or none, 2a: SR (with homogeneity) of cohort studies, 2b:
Individual cohort study, 2c: “Outcomes” Research; Ecological studies, 3a: SR (with homogeneity) of case-control studies, 3b: Individual Case-Control Study, 4:
Case-series (and poor quality cohort and case-control studies), 5: Expert opinion without explicit critical appraisal, or based on physiology, bench research or
“first principles
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Title, authors,
date, journal
An Internetbased
Approach for
Lifestyle
Changes in
Patients with
NAFLD: Twoyear Effects on
Weight Loss
and Surrogate
Markers

Purpose

Level of
Evidence

To
2a*
determine
the efficacy
of a webbased
educational
interventio
n targeting
lifestyle
changes to
promote
health
Arianna
eating
Mazzotti,
habits,
Maria Tuchese habitual
Caletti, Lucia
physical
Brodosi, Silvia activity,
Di Domizio,
and weight
loss in
Maria Luisa
patients
Forchielli,
Salvatore Petta, with nonalcoholic
Elisabetta
fatty liver
Bugianesi,
disease
Giampaolo
Bianchi, and
Giulio
Marchesini
2018

Sample

Design

716
patients
were
included
in the
study.
Participan
ts
underwent
either a
web-based
interventi
on or a
groupbased
interventi
on.

Cohort
observational
study

438
participate
d in a
threemonth
group
lifestyle
modificati
on
program.

Results

The group
lifestyle
modification
program
consisted of
healthy diet
counseling,
120-minute
weekly
sessions with
physicians
and
dietitians,
and the last
session with
a
psychologist
that
discussed
behavioral
strategies for
stimulus
control and
weight loss
maintenance.

56

Weaknesses Contribution:
Science and/or
Practice
Attrition rate
Large sample High
Findings of this
was higher in
size
number of
study suggests
females
cases were
that web-based
(p<0.001) and High attrition lost to
education can
in the grouprate
follow-up.
be beneficial in
based
patients with
intervention
Used
Limitations non-alcoholic
group
motivational included
fatty liver
(p<0.001) and interviewing using the
disease.
decreased
standard of
progressively
The goal of
care for the This study
in the web>10% weight control
proves that an
based group.
loss was
group. This internet-based
achieved and may have
cognitive and
The calorie
maintained at demonstrate educational
intake
two years.
d superiority program is
decreased in
of treatment useful for
the two cohorts Weight loss
approaches. patients with
was
(p=0.006).
non-alcoholic
accompanied
fatty liver
by reduction
Physical
disease and can
in liver
activity
promote
increased from enzymes.
lifestyle
baseline in
changes.
both groups
(p=0.183).
BMI decreased
progressively
in both groups

Strengths

Journal of
Hepatology

278
participate
d in a
web-based
program.

The webbased
program
consisted of
the group
program but
Mean age divided in
is 52 years four sessions.
old. 67%
were
males.
33% have
DM type
2.

(p=0.063),
average of
3.4% in the
web-based
intervention at
6 months,
4.9% at 12
months, 5.5%
at 24 months
(p<0.001).
About 20-28%
lost weight
>5% at
different time
points.
All liver
enzymes
decreased
significantly in
both groups at
6 (p<0.001),
12 (p<0.001),
and 24 months
(p=0.002).

*Oxford Centre for Evidence-Based Medicine: Levels of Evidence (2009)
1a: SR (with homogeneity*) of RCTs, 1b Individual RCT (with narrow Confidence Interval), 1c: All or none, 2a: SR (with homogeneity) of cohort studies, 2b:
Individual cohort study, 2c: “Outcomes” Research; Ecological studies, 3a: SR (with homogeneity) of case-control studies, 3b: Individual Case-Control Study, 4:
Case-series (and poor quality cohort and case-control studies), 5: Expert opinion without explicit critical appraisal, or based on physiology, bench research or
“first principles
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Title, authors,
date, journal

Purpose

Level of
Evidence

Sample

Design

Virtual
Consultations
Through the
Veterans
Administration
SCAN-ECHO
Project
Improves
Survival for
Veterans with
Liver Disease

To assess
the impact
of virtual
consultatio
ns (SCANECHO) on
all-cause
mortality
among
patients
with liver
disease

2b*

Regional
cohort of
patients
within the
VA system
(VISN 11)

Patients
included
were not
randomized.

Grace L. Su,
Lisa Glass,
Elliott B.
Tapper, Tony
Van, Akbar K.
Waljee, and
Anne E. Sales
2018
Hepatology

520
patients
who had
SCANECHO
visit were
included.
62,237
were
included
in the no
visit
cohort.
These
patients
did not
have a
traditional
in-person
hepatolog
y

Results

The SCANECHO group
had more
studies and
procedures
(variceal
The design
attempted to screen was
match patient 25% vs 15%).
characteristic
s between
The SCANcontrol and
ECHO group
cases
had
significantly
improved
survival and
were at
decreased risk
of death
(p=0.003)
compared to
the no visit
group. The
SCAN-ECHO
group had
similar
survival as
those with
traditional inperson visits.
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Strengths

Weaknesses Contribution:
Science and/or
Practice
Applied
Limitations Findings of this
propensity
included the study suggest
matching
possibility
that virtual
using broad
of not
consultations
demographic accounting
helped address
and clinical
all patient
issues of
characteristic differences
patients with
s to adjust for or
liver disease. In
effect
eliminating addition, the
estimates
confounding program
.
improved
The SCANprocess
The study
measures such
ECHO
consultations was limited as screening for
improved
to VA,
cancer and
which
varices.
screening
focused on a
procedures
and enhanced unique
population
survival
benefit for
patients with Generalizab
cirrhosis.
ility of the
findings
may be
The study
showed that
constrained
due to the
the benefits
limitations
of the
SCANabove.
ECHO

consultati
on.

The SCANECHO group
had no effect
on alcohol use
compared the
no visit group
(p>0.05).

Seven
were
excluded
due to
only
having an
abnormal
imaging
ICD-9
code. A
total of
513 were
included
(n=513).

showed after
a year.

The SCANECHO group
had a higher
rate of liver
cancer (25%
versus 15%)
compared to
the no visit
group.

Cohort
included
patients
with ICD9 code
that
matched a
liver
disease

The SCANECHO group
contributed to
improvements
in care quality
and higher
survival rates
than patients
with no visit.

*Oxford Centre for Evidence-Based Medicine: Levels of Evidence (2009)
1a: SR (with homogeneity*) of RCTs, 1b Individual RCT (with narrow Confidence Interval), 1c: All or none, 2a: SR (with homogeneity) of cohort studies, 2b:
Individual cohort study, 2c: “Outcomes” Research; Ecological studies, 3a: SR (with homogeneity) of case-control studies, 3b: Individual Case-Control Study, 4:
Case-series (and poor quality cohort and case-control studies), 5: Expert opinion without explicit critical appraisal, or based on physiology, bench research or
“first principles”
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Appendix C
Project Model
Step 1: Assess the need for change in
practice
• 1.8% or 4.5 million adults have liver
disease in the United States
• In 2017, 41,743 died from liver disease
in the United States, and more than 1.32
million died from cirrhosis globally
• CLD causes 1.75 million deaths each
year worldwide
• Patients with chronic liver disease are
more likely to have depressive
symptoms, poor health-related quality
of life (HRQoL), and lower health
utility score
• Chronic liver disease is associated with
higher health care expenditure. The
direct cost of chronic liver disease was
$2.5 billion, and the indirect cost was
$10.6 billion in 2004
• Patients with CLD receive suboptimal
care and fail to receive treatments as
recommended

Step 2: Locate the best evidence
• AASLD Guidelines
• PubMed and Embase search for literature
• Systematic reviews and meta-analyses

Step 3: Critically analyze the evidence
• Literature review
• Patients with CLD receive suboptimal
care and fail to receive treatments as
recommended
• CLD is associated with severe
complications and liver-related mortality.
• Intervention and medical advice provided
via telemedicine improved patient’s selfcare habits, including physical and
nutritional habits
• Telemedicine also improved survival rate
and increased quality of care
• Strong association between telemedicine
use, improved quality of care, and
improved patient outcomes

Step 5: Implement and evaluate change
in practice
• Provide monthly appointments with
patients via telemedicine
• Ongoing collaboration between the
multi-disciplinary team
• Ongoing assessment of outcomes
• Collect data at months 1, 3, and 6 or end
of intervention period
• Evaluate processes, outcomes, and costs
• Sustainability

Step 4: Design practice change
• Create a multi-disciplinary team to
follow the patients on a monthly basis
• Create a telemedicine infrastructure on
how patients will be managed by multiple
team members
• Collect baseline data prior to
implementation of intervention

Appendix C A model of evidence-based practice change to show the steps and schematic of the
DNP project. Source: Larrabee, J. H. (2009). Nurse to nurse: Practice. McGraw-Hill.
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Appendix D

Model for Improvement

Adapted PDSA Model for Improvement

What are we trying to accomplish?
Incorporate telemedicine to the current care model

How will we know that a change is an
improvement?
Ongoing assessment. Evaluate patient outcomes
What changes can we make that will result in
improvement?
Increase utilization of telemedicine to close the gap
on patient care

Act

Plan

Study

Do

Appendix D The model for improvement: PDSA. Source: Hickey, J. V., & Brosnan. (2017).
Evaluation of health care quality for DNPs (2nd ed.). Springer.
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Appendix E
The Chronic Liver Disease Questionnaire (CLDQ)
Younossi et al. (1999)
Response options:
1 All of the time
2 Most of the time
3 A good bit of the time
4 Some of the time
5 A little of the time
6 Hardly any of the time
7 None of the time
Questions:
1. How much of the time during the last two weeks have you been troubled by a feeling of
abdominal bloating?
2. How much of the time have you been tired or fatigued during the last two weeks?
3. How much of the time during the last two weeks have you experienced bodily pain?
4. How often during the last two weeks have you felt sleepy during the day?
How much of the time during the last two weeks have you experienced abdominal pain?
5. How much of the time during the last two weeks has shortness of breath been a problem for
you in your daily activities?
6. How much of the time during the last two weeks have you not been able to eat as much as
you would like?
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7. How much of the time in the last two weeks have you been bothered by having decreased
strength?
8. How often during the last two weeks have you had trouble lifting or carrying heavy objects?
9. How often during the last two weeks have you felt anxious?
10. How often during the last two weeks have you felt a decreased level of energy?
11. How much of the time during the last two weeks have you felt unhappy?
12. How often during the last two weeks have you felt drowsy?
13. How much of the time during the last two weeks have you been bothered by a limitation of
your diet?
14. How often during the last two weeks have you been irritable?
15. How much of the time during the last two weeks have you had difficulty sleeping at night?
16. How much of the time during the last two weeks have you been troubled by a feeling of
abdominal discomfort?
17. How much of the time during the last two weeks have you been worried about the impact
your liver disease has on your family?
18. How much of the time during the last two weeks have you had mood swings?
19. How much of the time during the last two weeks have you been unable to fall asleep at night?
20. How often during the last two weeks have you had muscle cramps?
21. How much of the time during the last two weeks have you been worried that your symptoms
will develop into major problems?
22. How much of the time during the last two weeks have you had a dry mouth?
23. How much of the time during the last two weeks have you felt depressed?
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24. How much of the time during the last two weeks have you been worried about your condition
getting worse?
25. How much of the time during the last two weeks have you had problems concentrating?
26. How much of the time have you been troubled by itching during the last two weeks?
27. How much of the time during the last two weeks have you been worried about never feeling
any better?
28. How much of the time during the last two weeks have you been concerned about the
availability of a liver if you need a liver transplant?
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Appendix F
Liver Disease Undernutrition Screening Tool
Casas Deza et al. (2021)
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Appendix G
Short-Form Patient Satisfaction Questionnaire (PSQ-18)
Marshall & Hays (1994)
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Appendix H
GANNT Chart – Telemedicine Timeline
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Figure 1
Weight Changes
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Figure 2
BMI Changes
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Figure 3
Liver-Related Hospitalization Changes
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Figure 4
Changes in the CLDQ Activity Domain
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Figure 5
Changes in the CLDQ Worry Domain
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Figure 6
Comparison of Visits 1 and 2 Outcomes
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Table 1
Comparison of CLDQ Outcomes in Mean ± SD by Domain

Domain

Visit 1 Mean ± SD

Visit 2 Mean ± SD

AS

4.99 ± 1.51

5.36 ± 1.33

FA

4.78 ± 0.95

4.8 ± 1.14

SS

4.98 ± 1.07

4.9 ± 1.38

AC

4.63 ± 1.73

5.73 ± 1.28

EF

5.23 ± 1.06

5.27 ± 0.98

WO

4.1 ± 1.29

3.34 ± 1.25

Total

4.82 ± 0.88

4.84 ± 0.87
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